Literature DB >> 27432930

Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6).

Jérémie H Lefevre1, Laurent Mineur1, Salma Kotti1, Eric Rullier1, Philippe Rouanet1, Cécile de Chaisemartin1, Bernard Meunier1, Jafari Mehrdad1, Eddy Cotte1, Jérome Desrame1, Mehdi Karoui1, Stéphane Benoist1, Sylvain Kirzin1, Anne Berger1, Yves Panis1, Guillaume Piessen1, Alain Saudemont1, Michel Prudhomme1, Frédérique Peschaud1, Anne Dubois1, Jérome Loriau1, Jean-Jacques Tuech1, Guillaume Meurette1, Renato Lupinacci1, Nicolas Goasgen1, Yann Parc1, Tabassome Simon1, Emmanuel Tiret1.   

Abstract

Purpose A pathologic complete response (pCR; ypT0N0) of a rectal tumor after neoadjuvant radiochemotherapy (RCT) is associated with an excellent prognosis. Several retrospective studies have investigated the effect of increasing the delay after RCT. The aim of this study was to evaluate the effect of increasing the interval between the end of RCT and surgery on the pCR rate. Methods GRECCAR6 was a phase III, multicenter, randomized, open-label, parallel-group controlled trial. Patients with cT3/T4 or Tx N+ tumors of the mid or lower rectum who had received RCT (45 to 50 Gy with fluorouracil or capecitabine) were included. Patients were randomly included in the 7-week or the 11-week (11w) group. Primary end point was the pCR rate defined as a ypT0N0 specimen (NCT01648894). Results A total of 265 patients from 24 centers were enrolled between October 2012 and February 2015. The majority of the tumors were cT3 (82%). After RCT, surgery was not performed in nine patients (3.4%) because of the occurrence of distant metastasis (n = 5) or other reasons. Two patients underwent local resection of the tumor scar. A total of 47 (18.6%) specimens were classified as ypT0 (four had invaded lymph nodes [8.5%]). The primary end point (ypT0N0) was not different (7 weeks: 20 of 133, 15.0% v 11w: 23 of 132, 17.4%; P = .5983). Morbidity was significantly increased in the 11w group (44.5% v 32%; P = .0404) as a result of increased medical complications (32.8% v 19.2%; P = .0137). The 11w group had a worse quality of mesorectal resection (complete mesorectum [I] 78.7% v 90%; P = .0156). Conclusion Waiting 11 weeks after RCT did not increase the rate of pCR after surgical resection. A longer waiting period may be associated with higher morbidity and more difficult surgical resection.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27432930     DOI: 10.1200/JCO.2016.67.6049

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  99 in total

1.  Role of the Interval from Completion of Neoadjuvant Therapy to Surgery in Postoperative Morbidity in Patients with Locally Advanced Rectal Cancer.

Authors:  Campbell S D Roxburgh; Paul Strombom; Patricio Lynn; Mithat Gonen; Philip B Paty; Jose G Guillem; Garrett M Nash; J Joshua Smith; Iris Wei; Emmanouil Pappou; Julio Garcia-Aguilar; Martin R Weiser
Journal:  Ann Surg Oncol       Date:  2019-04-08       Impact factor: 5.344

Review 2.  Management of the Complete Clinical Response.

Authors:  Angelita Habr-Gama; Guilherme Pagin São Julião; Bruna Borba Vailati; Ivana Castro; Debora Raffaele
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

3.  [Time interval between neoadjuvant radiochemotherapy and surgery in rectal cancer : No impact on the pathologic complete response rate?]

Authors:  Cihan Gani; Daniel Zips
Journal:  Strahlenther Onkol       Date:  2017-01       Impact factor: 3.621

4.  SSAT State-of-the-Art Conference: Advances in the Management of Rectal Cancer.

Authors:  Evie Carchman; Daniel I Chu; Gregory D Kennedy; Melanie Morris; Marc Dakermandji; John R T Monson; Laura Melina Fernandez; Rodrigo Oliva Perez; Alessandro Fichera; Marco E Allaix; David Liska
Journal:  J Gastrointest Surg       Date:  2018-09-13       Impact factor: 3.452

5.  Report from the 19th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29-30 September 2017.

Authors:  C A Kim; S Ahmed; S Ahmed; B Brunet; H Chalchal; R Deobald; C Doll; M P Dupre; V Gordon; R M Lee-Ying; H Lim; D Liu; J M Loree; J P McGhie; K Mulder; J Park; B Yip; R P Wong; A Zaidi
Journal:  Curr Oncol       Date:  2018-08-14       Impact factor: 3.677

6.  Changes in the multidisciplinary management of rectal cancer from 2009 to 2015 and associated improvements in short-term outcomes.

Authors:  C S D Roxburgh; P Strombom; P Lynn; A Cercek; M Gonen; J J Smith; L K F Temple; G M Nash; J G Guillem; P B Paty; J Shia; E Vakiani; R Yaeger; Z K Stadler; N H Segal; D Reidy; A Varghese; A J Wu; C H Crane; M J Gollub; L B Saltz; J Garcia-Aguilar; M R Weiser
Journal:  Colorectal Dis       Date:  2019-07-01       Impact factor: 3.788

7.  Cost analysis of a wait-and-see strategy after radiochemotherapy in distal rectal cancer.

Authors:  Cihan Gani; Ulrich Grosse; Stephan Clasen; Andreas Kirschniak; Martin Goetz; Claus Rödel; Daniel Zips
Journal:  Strahlenther Onkol       Date:  2018-07-09       Impact factor: 3.621

Review 8.  'Watch and wait' in rectal cancer: summary of the current evidence.

Authors:  Jason On; Emad H Aly
Journal:  Int J Colorectal Dis       Date:  2018-07-05       Impact factor: 2.571

9.  Colorectal Cancer Surgery During the COVID-19 Pandemic: A Single Center Experience.

Authors:  Davide Pertile; Marco Gipponi; Alessandra Aprile; Paola Batistotti; Carol Marzia Ferrari; Andrea Massobrio; Domenico Soriero; Lorenzo Epis; Stefano Scabini
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

10.  How Is Rectal Cancer Managed: a Survey Exploring Current Practice Patterns in Canada.

Authors:  A Crawford; J Firtell; A Caycedo-Marulanda
Journal:  J Gastrointest Cancer       Date:  2019-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.